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Abstract: The course of COPD is punctuated by acute exacerbations that are associated with an 
increase in the morbidity and mortality related to this chronic disease and may contribute to its 
rate of progression. Therefore, preventing and treating exacerbations are major goals of COPD 
management. The role of tiotropium in the prevention of exacerbations has been investigated in 
several placebo-controlled randomized clinical trials varying in duration from 3 months to 4 years 
in patients with moderate to very severe COPD. In all of these trials, tiotropium has uniformly 
reduced the proportion of patients experiencing at least one exacerbation and delayed the time 
to the first exacerbation compared with placebo. In the longer trials (6 months’ duration) 
tiotropium has also reduced the exposure-adjusted incidence rate of exacerbations. In trials of 
at least 1 year in duration, tiotropium either significantly reduced the risk of hospitalization for 
an exacerbation and/or the proportion of patients with an exacerbation-related hospitalization. 
In a meta-analysis that included 15 trials of tiotropium vs either placebo (n = 13) and/or a long-
acting beta-agonist (LABA; n = 4), tiotropium significantly reduced the odds of experiencing 
an exacerbation compared to placebo as well as a LABA. The potential additive benefits of 
tiotropium to those of a LABA and/or inhaled corticosteroid in reducing exacerbations require 
further investigation. The mechanism whereby tiotropium reduces exacerbations is not due to an 
anti-inflammatory effect but more likely relates to its property of causing a sustained increase 
in airway patency and reduction in hyperinflation, thereby counteracting the tendency for respi-
ratory insults to worsen airflow obstruction and hyperinflation. For the management of acute 
exacerbations, an increase in short-acting inhaled bronchodilators is recommended as needed, 
while the potential role of long-acting bronchodilators, such as tiotropium, in conjunction with 
short-acting agents, is unclear and warrants further study.
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Introduction and background
Definition
The clinical course of COPD is punctuated by acute exacerbations that have been 
defined as “a sustained worsening of the patient’s condition, from the stable state and 
beyond normal day-to-day variations, that is acute in onset and necessitates a change 
in regular medication in a patient with underlying COPD”.1 Specifically excluded 
from the definition are other causes of worsening symptoms, such as pneumonia, 
  congestive heart failure and pulmonary embolism. Another definition that has been 
used in clinical trials involving daily diaries requires a worsening of COPD symptoms 
for 2 consecutive days based on a diary card review in which patients report a 
worsening of at least 2 major symptoms (dyspnea, sputum volume and/or sputum International Journal of COPD 2010:5 42
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Frequency of exacerbations
Exacerbations occur with increasing frequency in rela-
tion to the severity of COPD. For example, in the 3-year 
ISOLDE trial of inhaled corticosteroids (ICS) in COPD,9 
the annual rate of HCU-defined exacerbations was 2.6, 1.7 
and 1.2 in those patients with an FEV1  1.25 L, 1.25 to 
1.54 L and  1.54 L, respectively. Using a symptom-based 
definition, Miravitilles et al10 reported a mean number of 
exacerbations per year of 2.3, 1.9 and 1.6 in patients with an 
FEV1 of 40%, 40% to 59% and 60%, respectively. In the   
4-year UPLIFT trial of tiotropium vs placebo, the proportion 
of subjects with 1 HCU-defined exacerbation per year was 
80%, 72% and 60% in those with GOLD severity stage IV , 
III and II, respectively.11 In a 1-year prospective observational 
study of 351 patients with COPD seen in a primary care set-
ting, those with mild to moderate disease had a mean number 
of exacerbations of 2.3, compared to 3.2 for patients with 
more severe disease.12 Thus, some patients with relatively 
mild disease may, like their more severe counterparts, also 
be predisposed to frequent exacerbations indicating increased 
susceptibility to these acute events.13 The most reliable 
predictor of a subsequent exacerbation in any given patient 
appears to be a history of previous exacerbations.13 It has 
been suggested that patients with frequent exacerbations (eg, 
2 per year) may represent a distinct phenotype of COPD,14 
with implications for targeted preventative therapy.
Impact of exacerbations
Exacerbations have a number of untoward consequences both 
for the patient and society. First, an exacerbation of COPD has 
a negative impact on health-related quality of life (HRQoL), 
or health status;15 a greater annual frequency of exacerba-
tions has been shown to be associated with higher scores on 
the St. George’s Respiratory Questionnaire, in which higher 
scores represent worse health status. Similarly, Spencer 
et al have shown that the greater the frequency of exacerba-
tions, the worse the annual rate of decline in health status.16 
Following treatment of an exacerbation, HRQoL improves 
over several weeks (indicating a reciprocal worsening of 
health status in the run-up to an exacerbation), but up to 
3 to 6 months may be required for health status to return to 
its pre-exacerbation level. Moreover, if another exacerbation 
occurs before an earlier one has completely resolved, health 
status may never return to baseline.16
Second, exacerbations are associated with a further 
impairment in lung function, contributing to the prominence 
of dyspnea as a major symptom. Since it is logistically dif-
ficult to track lung function prospectively in patients with 
color) or the occurrence of at least one minor symptom 
(sore throat, coryzal symptoms, otherwise unexplained fever 
and/or worsening cough or wheeze), as previously defined by 
Anthonisen et al.2 The severity of an exacerbation has been 
operationally defined as mild if symptoms are self-managed 
by the patient in his/her own normal environment (eg, by 
an increase in the use of rescue bronchodilator use) with-
out the use of antibiotics or oral corticosteroids, moderate 
if the patient seeks additional medical care and receives a 
prescription for an antibiotic and/or oral corticosteroids and 
severe if the exacerbation requires hospitalization because 
of rapid deterioration. Since it is generally not feasible to 
reliably ascertain a worsening of symptoms beyond normal 
day-to-day variation in the absence of daily diaries, exac-
erbations are commonly defined by more readily recalled 
events requiring health-care utilization (HCU) that result in 
a therapeutic intervention (usually treatment with antibiotics 
and/or oral corticosteroids). The duration of an exacerbation 
is highly variable and can last as long as 2 weeks, although 
some of the consequences of an exacerbation (such as 
worsening of airflow obstruction3 and further impairment 
in quality of life4) may require weeks to months to return to 
baseline and may never return to the pre-exacerbation level 
if an exacerbation recurs.
etiology
The cause of an acute exacerbation of COPD is most often 
infectious and related to a viral and/or bacterial infection.5 It 
is likely that the microbiome (ie, what organisms are present 
in the lungs) plays a critical role in predicting exacerbation 
rate. Sethi et al have shown an association between an 
  exacerbation and isolation of a new strain of a bacterial 
pathogen, supporting the causative role of bacteria in exac-
erbations of COPD.6 Noninfectious causes include climate 
change, worsening air pollution and noncompliance with 
the usually prescribed maintenance medication regimen. 
Airway inflammation plays an important role in the transi-
tion from the stable state to an exacerbation, as indicated by 
a substantial increase in both neutrophils and eosinophils 
in induced sputum during an exacerbation compared to the 
stable condition.7 Perera et al8 have shown that persistence of 
increased airway inflammation during treatment of an acute 
exacerbation of COPD, as indicated by persistently high 
levels of interleukin (IL) IL-6 and IL-8 in sputum, predicted 
a prolonged recovery time. Evidence of increased systemic 
inflammation (indicated by a high serum C-reactive protein 
concentration) 2 weeks after an exacerbation has also been 
shown to be a predictor of recurrent exacerbations.8International Journal of COPD 2010:5 43
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COPD to document the worsening of lung function that 
occurs during the development of an exacerbation, a strategy 
that has been used to determine the degree of impairment 
in lung function accompanying an evolving exacerbation is 
to perform serial measurements of lung function during the 
recovery phase of a treated exacerbation since any improve-
ment occurring during this phase must reflect reciprocal 
worsening that occurred during the run-up to an exacerba-
tion. Stevenson et al3 measured airflow (FEV1), airway 
resistance and inspiratory capacity (IC) for the first 3 days 
of a hospitalized exacerbation, at discharge and 42 days after 
admission. They found that lung function improved relatively 
little during the first 3 days of treatment but subsequently 
improved progressively up to 42 days along with a progres-
sive reduction in dyspnea, the improvement in inspiratory 
capacity being more than twice the magnitude of that in FEV1 
with relatively little change in airway resistance. These find-
ings indicate that exacerbations are associated with greater 
worsening of hyperinflation than of airflow and are consis-
tent with current concepts implicating hyperinflation as the 
major mechanism contributing to dyspnea during physical 
exertion.17 Similar findings were reported by Parker et al18 
who documented significant improvement in IC and recipro-
cal decreases in hyperinflation (functional residual capacity 
[FRC]) and air-trapping (residual volume [RV]) over the 
2 weeks of treatment of an acute exacerbation of moderate 
severity with parallel improvements in dyspnea. These find-
ings also provide a clue as to the mechanism whereby long-
acting inhaled bronchodilator therapy (eg, with tiotropium) 
might help prevent exacerbations. Tiotropium produces a 
sustained reduction in hyperinflation19 and improvement 
in airflow,20 thus raising the threshold for the perception of 
symptoms of dyspnea during insults to the lung that tend to 
worsen hyperinflation and airflow.
Third, it has also been argued that a greater frequency 
of exacerbations is associated with a greater rate of disease 
progression as reflected by a larger annual rate of decline in 
FEV1,21,22 although additional confirmation of this proposed 
association is required.
Fourth, acute exacerbations are associated with increased 
health-care utilization, increasing the cost of COPD both for 
the patient and society. Health care services for exacerbations 
account for 50% to 75% of all COPD costs.23 For patients 
who seek care as outpatients, the treatment failure rate 
varies from 13 to 33%.24 Of patients who receive treatment 
in an emergency department (ED), the relapse rate is 22% 
to 32%, often requiring a repeat ED visit.25 Approximately 
721,000 hospitalizations for a COPD exacerbation were 
reported in 2005.26 For patients hospitalized for COPD, the 
in-hospital mortality overall is ∼2.5%.27 However, for those 
requiring admission to an intensive care unit for hypercapnic 
ventilatory failure, the in-hospital mortality is 20% to 24%.28 
In a 4-year prospective study of 205 patients hospitalized 
for COPD, 8.3% died during their first admission, and 24%, 
33%, 39% and 49% died within 6 months, 1 year, 2 years 
and 4 years of admission, respectively. Thus, exacerbations 
are an important contributor to mortality in COPD.29
Because of the significant increase in morbidity and 
mortality from COPD exacerbations, the prevention and 
treatment of exacerbations are a major goal of COPD man-
agement according to current guidelines (GOLD) and a key 
outcome of interventional clinical trials.30
The role of tiotropium
Tiotropium has been found to be effective in preventing 
  exacerbations, but its potential role in the management of an 
acute exacerbation requires further study. This article reviews 
the evidence supporting its role in reducing exacerbations 
and the limited available data concerning its use in treating 
an exacerbation.
Preventing exacerbations
Several double-blind, randomized controlled clinical trials 
of 3 months to 1 year in duration comparing tiotropium 
with placebo have evaluated the efficacy of tiotropium in 
preventing exacerbations of COPD as either a key secondary 
endpoint31–33 or as a primary endpoint.34,35 For most of these 
studies exacerbations were defined as a complex of respira-
tory events (cough, wheezing, dyspnea or sputum produc-
tion) lasting 3 days and generally requiring treatment with 
antibiotics and/or oral corticosteroids. Exacerbations were 
detected through careful monitoring of adverse events. Severe 
exacerbations were defined as those requiring hospitalization. 
Analyses were performed using the intention to treat principle 
for all patients remaining on-treatment. Several different 
endpoints for exacerbations were used in these trials to a 
varying degree. These are enumerated below, along with the 
method used for analyzing each of the endpoints.
1.  Number of exacerbations treated with antibiotics 
and/or corticosteroids (ie, HCU-defined) per patient year. 
Between-group comparisons were made using Poisson 
regression with correction for treatment exposure and 
overdispersion.
2.  Proportion of patients with 1 HCU-defined exacerba-
tion. Proportions between treatment groups were com-
pared using Fisher’s exact test.International Journal of COPD 2010:5 44
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3.  Time to first HCU-defined exacerbation. Treatment 
groups were compared using log-rank tests and the hazard 
ratio (HR) was estimated using Cox regression.
4.  Number of exacerbation days per patient year. Poisson 
regression was used.
5.  Number of COPD exacerbations leading to hospitaliza-
tion per patient year. Poisson regression was used.
6.  Proportion of patients with 1 COPD exacerbation 
leading to hospitalization. Fisher’s exact test was used 
for between-group comparisons.
7.  The number of days hospitalized due to COPD exacerba-
tions per year, using Poisson regression for analysis.
8.  Time to the first COPD exacerbation leading to hospital-
ization with comparison between treatment groups using 
log-rank tests and the HR derived from Cox regression.
In a 1-year registration study (incorporating two identical 
clinical trials) of a total of 921 patients (mean baseline FEV1 
38.1%–39.1% pred; 40%–44% continued to use previously 
prescribed ICS), Casaburi et al31 showed that the proportion 
of patients experiencing 1 exacerbations was lower in the 
tiotropium group (36%) than the placebo group (42%) (14% 
reduction; P  0.05). Significantly fewer exacerbations were 
observed in the tiotropium group (0.76 events/patient-year) 
compared to the placebo group (0.95 event/patient-year) 
(20% reduction; P = 0.045), and a significant increase in the 
time to the first exacerbation was also noted in the tiotropium 
group relative to placebo (P = 0.011). Moreover, fewer hos-
pitalizations associated with exacerbations occurred in the 
tiotropium group (0.086 events/patient-year) compared to the 
placebo group (0.161 events/patient-year), a 47% reduction 
(P = 0.019), and the proportion of patients hospitalized for an 
exacerbation was lower in the tiotropium group (5.5%) than 
the placebo group (9.4%, 41% reduction, P  0.05).
In a 3-month study of 1639 patients (1236 tiotropium, 
403 placebo) with a mean FEV1 of 45.4% predicted, a COPD 
exacerbation occurred in a significantly lower proportion of 
tiotropium patients (14.6%) than placebo patients (19.9%) 
(26% reduction; P = 0.0151).32 The time to first exacerba-
tion was also prolonged in the tiotropium compared to the 
placebo group (P = 0.0092).
Brusasco et al33 compared health outcomes, including 
exacerbations, in a 6-month double-blind, double-dummy 
study of 1207 COPD patients (mean baseline FEV1 
37.7% -39.2% pred) who received tiotropium (n = 402), 
salmeterol (n = 405) or placebo (n = 400). Tiotropium-
treated patients had significantly fewer COPD exacerba-
tions (1.07) and exacerbation days (17.2) per patient-year 
than those treated with placebo (1.49 and 25, respectively). 
The reductions in exacerbations and exacerbations days per 
patient-yearr with tiotropium compared to placebo were 
28% and 31%, respectively (P = 0.025 for both). Tiotro-
pium also significantly delayed the time to the first COPD 
exacerbation compared with placebo (P  0.01). While 
tiotropium-treated patients had fewer hospital admissions 
for an exacerbation than placebo-treated patients, the dif-
ference was not statistically significant, nor did the time 
to the first hospital admission for a COPD exacerbation 
differ between the tiotropium and placebo groups, possibly 
due to the relatively small number of exacerbation-related 
hospitalizations during this 6-month study. Interestingly, 
however, significantly fewer all-cause hospital admissions 
occurred in the tiotropium than the placebo group (0.43 vs 
0.86, respectively; P  0.05). No significant differences 
were noted between the tiotropium and salmeterol treatment 
groups for any exacerbation variable.
The effect of tiotropium vs placebo on exacerbations 
was the primary aim of a multi-center, 1-year French study 
  (MISTRAL)34 that included 1010 subjects with a baseline 
FEV1 of 47.6% to 48.2% predicted. Continued use of ICS 
(reported at baseline by 61.6%–65.0% of the subjects) was 
permitted throughout the trial. For this study, an exacerbation 
was defined as the onset of 1 symptom (worsening dyspnea, 
cough or sputum; sputum purulence; fever) lasting  2 days 
and requiring a new prescription or an increase in the dose of 
β2-agonists, antibiotics, corticosteroids or bronchodilators. 
The severity of an exacerbation was defined as follows: mild 
– one or two of the above symptoms; moderate – 3 of the 
above symptoms excluding a severe exacerbation; severe 
– exacerbation requiring hospitalization or meeting at least 
one criterion based on pre-defined drops in FEV1 and/or peak 
expiratory flow or defined changes in PaO2 and/or PaCO2. 
For comparison with the results of other studies, a more 
generalized HCU-based definition of exacerbation sever-
ity was used: severe – requiring hospitalization; moderate 
– requiring treatment with systemic steroids and/or antibiot-
ics; mild – all remaining exacerbations. The proportion of 
patients experiencing 1 exacerbations during the 1-year 
treatment period was significantly lower in the tiotropium 
than the placebo group (17% reduction; P  0.01). Moreover, 
tiotropium-treated patients had significantly fewer COPD 
exacerbations (35% reduction; P  0.001) and exacerba-
tion days (37% reduction; P  0.001) than placebo-treated 
patients, and tiotropium significantly delayed the time to 
the first exacerbations by ∼100 days compared with placebo 
(P  0.001). Using the generalized definition of exacerbation 
severity, tiotropium reduced the proportion of patients International Journal of COPD 2010:5 45
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experiencing 1 moderate to severe exacerbation by 20% 
(P  0.001) and reduced the number of moderate to severe 
exacerbations by 35% (P  0.001) compared to placebo. 
While tiotropium resulted in numerically fewer exacerba-
tion-related hospitalizations and hospital days, the differences 
from placebo were not statistically significant. Tiotropium 
significantly reduced the number of exacerbations compared 
with placebo, irrespective of COPD severity (ie, FEV1  
or  50% predicted). Although tiotropium numerically 
reduced exacerbations irrespective of concomitant ICS use 
or exacerbation history during the year preceding the trial, 
this reduction failed to reach statistical significance in those 
not receiving concomitant ICS or those with infrequent 
exacerbations in the preceding year.
A 6-month placebo-controlled trial involving 26 Veterans 
Affairs medical centers in the US was conducted to evalu-
ate the efficacy of tiotropium in preventing exacerbations of 
COPD as the primary outcome.35 A unique feature of this 
study was the permissive use during the entire treatment 
period of all prescribed concomitant respiratory medication 
(including ICS and long-acting beta-agonists [LABAs]), other 
than anticholinergic medication, in addition to the study drug, 
thus mimicking “real-world” conditions. Another unique 
feature of this study was its ability to track lower respiratory 
serious adverse events (SAEs), essentially capturing exac-
erbation-related hospitalizations, using electronic medical 
records from the VA system even in patients who prematurely 
withdrew from the trial.36 Randomized participants included 
1829 patients with moderate to severe COPD (mean base-
line FEV1 36% predicted), 98%–99% of whom were male. 
Tiotropium significantly reduced the percentage of patients 
experiencing 1 exacerbation during the 6-month trial com-
pared to placebo (27.9% vs 32.3%, respectively; P = 0.037). 
Tiotropium also reduced the percentage of patients with 1 
exacerbation-related hospitalization compared to placebo 
(7.0 vs 9.5%), although this difference just missed statisti-
cal significance (P = 0.056). The analysis assumed that the 
47 tiotropium patients (5.1%) and 66 placebo patients (7.2%) 
who withdrew from the study before an event had no event. 
However, when incidence rates of serious (hospitalized) 
exacerbations per 100 patient-years were calculated for those 
subjects who prematurely discontinued the trial, these rates 
were ∼2-fold higher in the placebo group during the remain-
der of the protocol-defined trial period after premature cessa-
tion of the study drug (22.1) than during the actual treatment 
period prior to premature withdrawal from the trial (12.4). 
In contrast, the rates were similar for these two periods in 
the tiotropium group (9.2 vs 8.8, respectively).36 Since more 
placebo than tiotropium patients withdrew prematurely from 
the treatment phase of the study, these findings imply a bias 
in favor of placebo if the analysis included only events that 
occurred during actual treatment with the study drug.
Analysis of secondary outcomes from the VA trial 
showed that tiotropium prolonged the time to the first exac-
erbation (HR 0.83 [95% confidence interval, CI, 0.70–0.98]; 
P = 0.028), as well as to the first exacerbation-related hospital-
ization (HR 0.73 [CI, 0.53–1.01]; P = 0.055), although the lat-
ter finding was of borderline statistical significance. Compared 
to placebo, tiotropium also reduced the overall frequency of 
exacerbations by 19% (P = 0.031) and of hospitalizations 
due to exacerbations by 28% (P = 0.047) and decreased the 
number of exacerbation days by 21% (P = 0.019). In subgroup 
analyses of the VA trial data, tiotropium nearly uniformly 
reduced exacerbations for all subsets included in the analysis: 
age (70, 61–70 and 61 years), current smoking, FEV1 
(49%, 35%–49% and 35% predicted), hospitalization in 
the past year, antibiotic use in the past year, home oxygen use, 
ICS use, LABA use and theophylline use (Figure 1). These 
results imply a benefit of tiotropium in reducing exacerbations 
when used in conjunction with other prescribed long-acting 
inhaled respiratory medication.
In addition to the aforementioned study of Brusasco et al,33 
which compared the impact of tiotropium with that of salme-
terol (as well as placebo) on exacerbations, two additional 
reports compared the effect of tiotropium on exacerbations 
with that of another active comparator, ipratropium37 or 
salmeterol.38 The results of two identical multi-center 1-year 
trials in Belgium and the Netherlands of tiotropium once 
daily (n = 356) vs ipratropium four times daily (n = 179) in 
patients with a mean FEV1 of 39.4% to 41.9% predicted were 
combined into a single report.37 Over 80% of the patients con-
tinued to use prescribed ICS during the trial. The proportion 
of patients with 1 exacerbations during the 1-year treatment 
period was significantly lower in the tiotropium group (35%) 
than the ipratropium group (46%) (P = 0.014). The number 
of exacerbations per patient-year was 0.73 in the tiotropium 
group and 0.96 in the ipratropium group (24% reduction with 
tiotropium, P = 0.006). Furthermore, the number of exacerba-
tion days/patient-year was 39% lower in the tiotropium group 
(10.8 vs 17.7 in the ipratropium group; P = 0.002). The time 
to first exacerbation was significantly longer in the tiotropium-
treated patients (P = 0.008). Similar findings were noted for 
hospitalized exacerbations, although most of these failed to 
reach statistical significance. The proportion of patients with 
an exacerbation-related hospitalization was 7.3% and 11.7% in 
the tiotropium and ipratropium groups, respectively (P = 0.11). International Journal of COPD 2010:5 46
Tashkin Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The number of hospitalizations per patient-year was 39% lower 
in the tiotropium group (0.10 vs 0.16, P = 0.08). Furthermore, 
the time to first hospitalized exacerbation was significantly 
longer in the tiotropium-treated patients (P = 0.048). These 
findings are all the more remarkable since ipratropium itself 
has been shown to reduce exacerbation frequency significantly 
compared with regularly scheduled albuterol alone.39
Another study compared the efficacy of tiotropium once 
daily with that of salmeterol 50 mcg twice daily over 12 weeks 
in 563 patients with a mean FEV1 of 37.7% predicted.38 In 
this short-term study the overall incidence of COPD exac-
erbations was low and the percentage of patients with 1 
exacerbation was fairly comparable between the tiotropium 
and salmeterol groups (9 vs 11%, respectively, P = 0.37), as 
Odds Ratio for ≥1 COPD Exacerbation
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
Favors tiotropium Favors placebo
Characteristic
Overall (n = 1829)
Age
>70 y (n = 756)
<61 y (n = 400)
61–70 y (n = 673)
Current smoker
No (n = 1294)
Yes (n = 535)
No (n = 1543)
Yes (n = 286)
No (n = 1334)
Yes (n = 492)
No (n = 1001)
Yes (n = 826)
No (n = 1298)
Yes (n = 531)
No (n = 787)
Yes (n = 1041)
No (n = 1115)
Yes (n = 713)
No (n = 1564)
Yes (n = 264)
FEV1
>49% predicted (n = 287)
35%–49% predicted (n = 610)
<35% predicted (n = 931)
Hospitalization in the past year
Prednisone use in the past year
Antibiotic use in the past year
Home oxygen use
Inhaled steroid use
Long-acting β-agonist use
Theophylline use
Figure 1 Odds ratios and 95% confidence intervals (CIs) for reduction in first COPD exacerbation with tiotropium according to selected baseline characteristics. Numbers 
in parentheses represent sample size for that subset. Error bars represent 95% CIs. Reproduced with permission from Niewoehner DE, Rice K, Cote C, et al. Prevention of 
exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med. 2005;143:317–26.35 Copyright © 
2005 American College of Physicians.International Journal of COPD 2010:5 47
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was the frequency of exacerbations, exacerbation days and 
time to first exacerbation. Non-significantly fewer tiotropium- 
than salmeterol-treated patients experienced an exacerba-
tion-related hospitalization (4 vs 9, respectively; P = 0.16). 
Thus, the results of this study were consistent with those 
of the 6-month study of Brusasco et al33 with respect to the 
lack of significant differences between tiotropium and sal-
meterol in preventing exacerbations, although the relatively 
short duration of these trials may have reduced the ability to 
demonstrate possible differences between the two treatments 
in their effects on exacerbations.
The effects of tiotropium in preventing HCU-defined 
exacerbations (requiring treatment with oral corticosteroids 
and/or antibiotics or hospitalization) were also compared 
with those of the salmeterol/fluticasone combination 
(SFC) in a 2-year study (INSPIRE) of 1323 patients with 
severe/very severe COPD (mean baseline FEV1 39.4% 
predicted).40 The primary endpoint was the mean annual 
number of HCU-defined exacerbations. The annual exacer-
bation rate was essentially the same in the tiotropium and 
SFC groups: 1.32 and 1.28, respectively; incidence rate 
ratio 0.97 [95% CI, 0.84-1.12]; P = 0.66). On the other 
hand, the nature of the exacerbations differed between the 
two groups in that a significantly lower rate of exacerba-
tions treated with oral corticosteroids was noted in the SFC 
than the tiotropium group (0.69 vs 0.85, respectively; rate 
ratio 0.81 [95% CI, 0.67-0.99]; P = 0.039), while a signifi-
cantly higher rate of exacerbations treated with antibiotics 
was observed in the SFC than the tiotropium group (0.97 
vs 0.82, respectively; rate ratio 1.19 [95% CI, 1.02–1.38]; 
P = 0.028).
The higher rate of exacerbations requiring oral cortico-
steroids in the tiotropium group might possibly reflect the 
need for an anti-inflammatory agent by some of these patients 
for protection against exacerbations. This could have been 
particularly true for the ∼50% of the tiotropium subjects who 
had been receiving ICS prior to the trial, since withdrawal of 
ICS in these subjects at trial entry could have predisposed 
them to an exacerbation requiring oral corticosteroids after 
the potentially beneficial effects of the initial two-week 
course of oral prednisolone (which all patients in the trial 
received during a 2-week run-in period of intensified therapy) 
wore off. An increased risk of a COPD exacerbation after 
withdrawal of ICS has been reported previously.41,42
On the other hand, the higher rate of exacerbations requir-
ing antibiotics in the SFC group might have been due to 
fluticasone-induced impairment of local immune resistance to 
lower respiratory infection since the incidence of pneumonia 
with SFC was twice as high as that with tiotopium (8 vs 4%, 
respectively; HR 1.94 [95% CI, 1.19-3.17]; P = 0.008). The 
latter findings are also consistent with the an increase in 
pneumonia incidence in the fluticasone-containing arms of 
the TORCH trial,43 an increased risk of pneumonia with ICS 
in a recent meta-analysis44 and an increased risk of pneumo-
nia hospitalizations with ICS in an observational study.45 In 
contrast, tiotropium has not been found to be associated with 
an increased incidence of pneumonia.20
The two co-primary endpoints of the recent 4-year Under-
standing Potential Long-Term Impacts on Function with 
Tiotropium (UPLIFT) trial of tiotropium vs placebo were 
the annual rates of change in pre- and post-bronchodilator 
FEV1 over 4 years, testing the hypothesis that tiotropium 
might influence the natural progression of COPD.20 Nearly 
6000 patients (2896 on tiotropium and 3006 on placebo) with 
moderate, severe or very severe COPD (45%–46%, 44% 
and 8%–9%, respectively), including ∼25% females, were 
studied. The impact of tiotropium vs placebo on exacerba-
tions and related hospitalizations was a pre-specified, key 
secondary endpoint. A unique feature of this global study 
involving 490 investigational centers in 37 countries was 
the permissive use of all concomitant prescribed respiratory 
medication, in addition to the study drug, over the course 
of the trial, with the exception of inhaled anticholinergics. 
Tiotropium resulted in a significant delay in the time to 
the first exacerbation compared to placebo with a reduc-
tion in the risk of exacerbations by 14% (HR 0.86 [95% 
CI, 0.81-0.91]; P  0.001). Tiotropium also significantly 
reduced the frequency of exposure-adjusted exacerbations 
(number per patient-year) (0.73 ± 0.02) compared to placebo 
(0.85 ± 0.02) with a relative risk of 0.86 [95% CI, 0.81-0.91; 
P  0.001]. In addition, tiotropium reduced the risk of 
exacerbation-related hospitalization by 14% (HR 0.86 [95% 
CI, 0.78-0.95]; P = 0.002). Complementing the latter benefit 
was the finding that tiotropium reduced the incidence (per 
100 patient-years) of serious lower respiratory adverse events, 
including the incidence of respiratory failure.
In a sub-group analysis of the 2739 GOLD stage II 
subjects (mean FEV1 59% predicted) within the larger total 
UPLIFT trial population, time to first exacerbation and 
time to first exacerbation resulting in hospital admission 
were significantly longer in the tiotropium than the placebo 
group (HR 0.82 [95% CI, 0.75–0.90] and 0.74 [95% CI, 
0.62-0.88], respectively).11 These findings indicated at least 
comparable benefits of tiotropium in reducing exacerbations 
in patients with moderate COPD compared to those with 
severe disease, despite the fact that the former subjects had International Journal of COPD 2010:5 48
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fewer exacerbations than the latter in both treatment groups. 
Another subgroup analysis compared the impact of tiotro-
pium on exacerbations in relation to differing smoking status 
during the course of the trial, defined as continuing smoking, 
continuing ex-smoking and intermittent smoking.46 The rate 
ratios (RR; tiotropium/placebo) for the number of exacerba-
tions per patient-year were roughly comparable across these 
different patterns of smoking during the study, ranging from 
0.83 to 0.90, although a significant reduction in exacerba-
tions with tiotropium was observed only in the continuing 
ex-smokers (RR 0.83 [95% CI, 0.77-0.90]), who comprised 
the largest proportion of the study population (∼60%).
While a formal subgroup analysis of the UPLIFT data 
by concomitant LABA and/or ICS use has not yet been 
completed, it appears that the benefits of tiotropium on 
most outcomes, including reduction in exacerbations, were 
achieved irrespective of concurrent use of other prescribed 
long-acting inhaled respiratory medication (which was 
reported by over 60% of the participants at baseline and over 
70% over the course of the trial). If this result is confirmed, 
the implications are that tiotropium may add to the benefit 
of existing LABA and/or ICS use in reducing exacerbations 
since the latter medications when used as monotherapy or 
in combination have previously been shown to be effective 
in preventing exacerbations.43
On the other hand, the results of the Canadian Optimal 
Treatment of COPD trial47 failed to show a significant addi-
tive effect of salmeterol or of the SFC combination when 
administered in addition to tiotropium on HCU-defined 
exacerbations (the primary endpoint). This study was a 
1-year multi-center, randomized, double-blind, placebo-
controlled trial of tiotropium once daily alone compared 
with the addition of either salmeterol (50 µg) twice daily or 
the SFC (500 µg fluticasone/50 µg salmeterol) twice daily 
to tiotropium once daily in 449 patients with moderate to 
severe COPD (mean baseline post-bronchodilator FEV1 
41.2%-42.2% predicted) with a history of 1 exacerbation 
of COPD in the previous year. Over the 1-year treatment 
period, the “triple” combination (tiotropium plus SFC) did 
not result in any significant difference from tiotropium alone 
in the proportion of patients with 1 COPD exacerbation 
(60% vs 62.8%, respectively) or a significant reduction in 
the risk of an exacerbation compared to tiotropium alone 
(HR 0.80 [95% CI, 0.60–1.08); P = 0.15). On the other hand, 
compared to tiotropium alone, the “triple” combination did 
result in a significantly reduced incidence rate ratio for severe 
exacerbations, defined as exacerbation-related hospitaliza-
tions (0.53 [95% CI, 0.33–0.86]). This study may have been 
underpowered to detect a significant difference in the primary 
endpoint. Moreover, salmeterol appears to be a less effective 
LABA than formoterol, as suggested by the failure of the 
salmeterol/tiotropium combination in this Canadian study to 
produce a significantly greater trough FEV1 after 1 year of 
therapy than tiotropium alone, in contrast to findings from 
several studies that the combination of tiotropium and for-
moterol produces additive bronchodilation over tiotropium 
alone, including additive effects in reducing hyperinflation, 
as recently summarized by Cazzola and Tashkin.48 It is pos-
sible, therefore, that the combination of tiotropium with either 
formoterol alone or formoterol plus an ICS could result in 
additive benefits with respect to preventing exacerbations. 
Additional well-designed and adequately powered studies 
are required to explore this possibility.
Meta-analysis
A recent meta-analysis of randomized controlled trials, 
including 15 trials of tiotropium vs placebo and/or an 
active comparator (13 vs placebo; 3 vs salmeterol and 1 vs 
formoterol) examined the impact of tiotopium in reducing 
  exacerbations.49 The results indicated a significantly reduced 
odds of experiencing an exacerbation with tiotropium vs 
placebo (odds ratio [OR] 0.69 [95% CI, 0.61–0.78]), as well 
as with tiotropium vs LABA (OR 0.82 [95% CI, 0.72-0.93]). 
Using a mixed treatment comparison meta-analysis, the 
authors also found a significantly reduced odds of experienc-
ing an exacerbation with tiotropium vs ICS (OR 0.81 [95% 
CI, 0.69-0.94]) and a nonsignificant reduction in the odds 
ratio for tiotropium vs ICS/LABA combination (OR 0.91 
[95% CI, 0.78-1.04]).
Putative mechanism of exacerbation 
reduction with tiotropium
Since most exacerbations are considered to have an infec-
tious etiology5 and are associated with an increase in airway 
inflammation,7,8 the mechanism whereby a long-acting 
bronchodilator such as tiotropium might reduce or prevent 
exacerbations is unclear. Although tiotropium has been shown 
to have anti-inflammatory properties in cell-based studies,50,51 
the clinical significance of these has not been demonstrated. 
To investigate the possibility that tiotropium might reduce 
exacerbations in part through an anti-inflammatory mecha-
nism, Powrie et al52 studied the effect of a 1-year treatment 
with tiotropium vs placebo in 142 patients with COPD (mean 
FEV1 ∼50% predicted) on sputum and serum inflamma-
tory markers (sputum IL-6, IL-8 and MPO and serum IL-6 
and CRP) at the same time that they examined the effect International Journal of COPD 2010:5 49
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on exacerbations. Tiotropium resulted in a 52% reduction in 
the rate of exacerbations per patient year compared to placebo 
(1.17 ± 2.25 [SD] vs 2.46 ± 3.82, respectively; P = 0.007) and 
a significant delay in the time (in days) to the first exacerba-
tion (236 ± 143 vs 157 ± 124 days, respectively; P = 0.009). 
However, no differences in sputum or serum inflammatory 
markers were noted between tiotropium and placebo over the 
year-long study. The authors concluded that the reduction in 
exacerbations with tiotropium is unlikely to be mediated by 
a reduction in airway or systemic inflammation.
One possible mechanism whereby tiotropium might 
reduce exacerbations may be through improved clearance 
of respiratory secretions resulting from the bronchodilator-
induced increase in airway patency.53 Another possible 
mechanism may be mediated through the sustained improve-
ment in airflow and reduction in hyperinflation due to its 
long-acting bronchodilator properties20,54 that result in a 
reduction in dyspnea.31,19,55 Exacerbations are associated 
with worsening lung function,3,18 including an increase 
in hyperinflation, that results in increasing dyspnea that 
leads the patient to seek medical attention, thus fulfilling 
a HCU-defined exacerbation. It is possible, therefore, that 
the sustained improvement in lung function achieved with a 
24-hour-acting bronchodilator might raise the threshold for 
the perception of symptoms in response to various insults 
(including a respiratory tract infection) that might other-
wise cause a critically severe impairment in lung function 
to a degree that produces symptoms that the patient deems 
  warrants medical attention.
Potential limitations
Clinical trials that evaluate the impact of a therapeutic 
intervention on exacerbations, including the ones included 
in this review, are subject to a number of potential limita-
tions.56,57 First, exacerbations are defined in different ways 
and there may be uncertainty as to the true occurrence of 
an exacerbation in accord with the pre-specified definition 
of an exacerbation (whether symptom- or event-based) that 
is ideally resolved using an independent, blinded adjudi-
cation process. Unfortunately, the latter process is rarely 
implemented. Second, it may be difficult, in some cases, 
to distinguish between a new exacerbation and one that is 
slow to resolve or has relapsed. This limitation would affect 
analyses of the frequency or rate of exacerbations but not a 
“survival curve” analysis of the time to the occurrence of the 
first exacerbation. Third, in most clinical trials there is no 
attempt to capture exacerbations after the patient prematurely 
withdraws from the trial. (The VA cooperative trial35,36 and 
Canadian Optimal Treatment trial47,56 are rare exceptions). 
This creates a potential bias since exacerbation rates are much 
higher after premature discontinuation of study drug.36,57 
This bias can only partially be adjusted for by a weighted 
statistical approach that takes into account the time spent in 
the trial, a method used in most of the trials reviewed herein. 
Fourth, variations in the effect of treatment between subjects 
assigned to different arms of a parallel-group study leads to 
overdispersion of residuals in the usual parametric analysis, 
causing inappropriate narrowing of the confidence intervals; 
this can be corrected by using a Poisson distribution with 
adjustment for overdispersion or by using a negative binomial 
error distribution.58,59 Such techniques were applied to the 
analysis of the exacerbation data in most of the tiotropium 
trials included in this review.
Managing exacerbations
According to current COPD guidelines,30 long-acting 
inhaled bronchodilators, such as tiotropium, have no defined 
role in the management of acute exacerbations. The home 
management of exacerbations involves increasing the dose 
and/or frequency of existing short-acting bronchodilators, 
preferably with a β2-agonist, although, despite the absence 
of compelling evidence of the additional benefit of combina-
tions of short-acting bronchodilators, it is suggested that an 
anticholinergic bronchodilator can be added until symptoms 
improve. Systemic corticosteroids are also recommended 
for 7 to 10 days in addition to bronchodilators because of 
evidence that they shorten recovery time, improve lung func-
tion and hypoxemia and reduced the risk of early relapse or 
treatment failure. In addition, antibiotics are recommended 
for patients with increased sputum purulence in addition to 
increased dyspnea and/or increased sputum volume and for 
patients with severe exacerbations requiring either invasive 
or noninvasive mechanical ventilation. For patients hospital-
ized for a COPD exacerbation, supplemental oxygen therapy 
is recommended, along with bronchodilators, systemic 
corticosteroids and, under the circumstances noted above, 
antibiotics. Patients not responding favorably to these mea-
sures may require mechanical ventilatory assistance, either 
noninvasive (preferred) or with intubation.
Regarding the choice of bronchodilators in either 
the home or the hospital setting, short-acting inhaled   
β2-agonists are usually preferred, but, if a prompt response 
does not occur, the addition of a short-acting anticholinergic 
(ipratropium) is recommended. Unfortunately, few studies 
have evaluated the use of long-acting inhaled bronchodila-
tors (either LABAs or tiotropium) during an exacerbation.   International Journal of COPD 2010:5 50
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Di Marco et al60 examined the effect of tiotropium once daily, 
formoterol twice daily and their combination administered 
using a 3-way crossover design with a random sequence to 21 
patients (mean FEV1 38% ± 14% predicted) during an acute 
exacerbation of COPD managed outside the hospital. Lung 
function was measured serially over 24 hours during each 
medication sequence. Mean FEV1, FVC and IC AUC0–12 h and 
AUC0–24 h after the combination of tiotropium and formoterol 
were significantly higher compared to either drug alone, while 
no significant differences were noted between tiotropium and 
formoterol monotherapy. Interestingly, the bronchodilating 
effects of each regimen were shorter in the setting of an acute 
exacerbation than has been generally observed in patients 
with stable COPD and, by 24 hours, had disappeared with 
the exception of a significant residual improvement in FEV1 
with the combination only. This curtailment in the duration 
of action of these long-acting bronchodilators during an 
exacerbation may be due to several factors. One factor may be 
less effective delivery of the inhaled medication to the lower 
respiratory tract during an exacerbation due to the associated 
increase in airways obstruction from increased inflamma-
tion, airway mucus and bronchospasm. Another factor may 
involve functional antagonism, in which constrictor stimuli 
may be enhanced during an exacerbation, possibly related to 
the increase in inflammation, thereby requiring a greater dose 
and/or duration of bronchodilators to counteract the enhanced 
bronchoconstrictor tendency. The clinical implications of 
these findings regarding the bronchodilator management of 
acute exacerbations are that regularly scheduled long-acting 
inhaled bronchodilators and, in particular, the combination of 
tiotropium once daily and a LABA twice daily, have poten-
tial benefits for the management of an acute exacerbation, 
although additional treatment with short-acting bronchodila-
tors is most likely required, together with the longer-acting 
agents, because of the shortened duration of action of the latter 
during an exacerbation compared to the stable state.
Drescher et al61 recently published the results of a single-
center study concerning the possible benefits of incorporating 
long-acting inhaled bronchodilators (specifically tiotropium 
once daily and formoterol twice daily) into a respiratory-
therapist directed program for the hospital management of 
severe COPD exacerbations in nonventilated patients. Since 
the authors had previously incorporated twice-daily treatment 
with formoterol into its inpatient program for managing 
COPD exacerbations,62 the addition of tiotropium to this pre-
existing program resulted in a new program of combination 
long-acting inhaled bronchodilator therapy. In addition to this 
combination of long-acting inhaled bronchodilators, patients 
received treatments with short-acting agents (β2-agonist 
and/or anticholinergic) as needed. The primary outcome of 
this retrospectively analyzed study was the total number of 
as-needed short-acting bronchodilator treatments per patient 
per admission following the implementation of the new 
inpatient bronchodilator program in comparison with similar 
data collected during a previous historical period when 
formoterol alone was routinely administered twice daily. 
Therefore, the differences between the two periods reflected 
primarily the novel addition of tiotropium to the pre-existing 
bronchodilator regimen. The authors found that the addition 
of tiotropium resulted in a significant reduction in the number 
of short-acting bronchodilator treatments per admission, as 
well as a significant reduction in the length of hospital stay 
of ∼1 day, compared to the historical control group treated 
during the same season of the year (winter months); these 
benefits translated into a pharmacoeconomic advantage. The 
authors also found that tiotropium use in the in-hospital set-
ting was well-tolerated without adverse events, despite the 
occasional concomitant use of ipratropium in combination 
with a short-acting inhaled β2-agonist.
The benefits of a therapeutic regimen for patients hospital-
ized with an exacerbation of COPD that includes the regular 
once or twice daily administration of two long-acting inhaled 
bronchodilators (tiotropium and a LABA) with complemen-
tary mechanisms of action are likely due to the prolonged, as 
well as additive, improvements in airway patency from the 
two drugs that minimize the need for additional as-needed 
therapy with short-acting bronchodilators and their associated 
costs. The major limitations of this study are its retrospective 
design, the use of historical controls and the small numbers 
of subjects studied during each period (n = 174 and n = 181). 
The findings need to be replicated using a controlled, pro-
spective, multi-institutional study design (randomized by 
institution or subject) with larger total sample sizes before 
the results can be generalized to the general population of 
COPD patients hospitalized with an acute exacerbation not 
requiring intubation.
Another question raised by the study of Drescher et al61 
concerns the added efficacy (as well as the safety) of 
ipratropium when administered on an as-needed basis on 
top of twice-daily therapy with tiotropium in the in-hospital 
treatment of COPD exacerbations. Little data are available 
that address this question and what data that do exist were 
obtained in outpatients with stable COPD on maintenance 
therapy with tiotropium in whom the add-on short-term 
responses to ipratropium were compared with those of 
both placebo and a short-acting β2-agonist, fenoterol.63 In International Journal of COPD 2010:5 51
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the latter study, conducted in 60 patients, the 1-hour FEV1 
placebo-adjusted response to ipratropium vs placebo (on top 
of maintenance tiotropium) was 69 mL (95% CI, 34-105; 
P = 0.0002) after the first dose and 47 mL (95% CI, 12–83; 
P = 0.008) after the second dose. However, the correspond-
ing placebo-adjusted responses to fenoterol were signifi-
cantly (P  0.0001) greater: 154 mL (95% CI, 119-189; 
P  0.0001) and 208 mL (95% CI, 173-243; P  0.0001), 
respectively. There was no evidence of any increase in the 
frequency or intensity of adverse events after the addition 
of either ipratropium or fenoterol in these patients on exist-
ing tiotropium therapy. Thus, while the addition of a short-
  acting anticholinergic on top of a long-acting anticholinergic 
appears to result in significant additive bronchodilation, this 
benefit is less than that achieved with the add-on of a short-
acting β2-agonist, as expected due to the known complemen-
tary action of combining two bronchodilators with different 
pharmacologic mechanisms. Furthermore, it is not clear that 
adding the combination of ipratropium and a short-acting 
β2-agonist to an existing long-acting anticholinergic regimen 
would provide any advantage over the simple addition of 
the short-acting β2-agonist alone. On the other hand, since 
it has been shown that long-acting bronchodilators are less 
effective during an acute exacerbation of COPD than in 
stable patients,60 the addition of short-acting bronchodila-
tors of both classes may have different effects (both alone 
and in combination) in patients during an exacerbation from 
those evident in stable patients. Further studies are required 
to address these questions.
Safety of tiotropium
Cardiovascular events
Doubts about the safety of tiotoprium were raised prin-
cipally by a recent meta-analysis of 12 tiotropium trials 
by Singh et al64 who reported an elevated risk ratio (1.58 
[95% CI, 1.21-2.06]) for tiotropium vs its comparator for 
a composite of cardiovascular events (cardiovascular death, 
nonfatal myocardial infarction [MI] and nonfatal stroke), as 
well an increased risk ratio, separately, for cardiovascular 
death (1.80 [95% CI, 1.17-2.77]) and for MI (1.53 [95% 
CI, 1.05-2.23]). This meta-analysis has been criticized for 
relying mainly on summary (rather than patient-level) data 
and for failing to control for differential exposures to the 
study drugs. Since more placebo/comparator patients than 
tiotropium-treated patients discontinued these trials prema-
turely, the latter were at increased risk of fatal and nonfatal 
adverse events simply because of their longer duration of 
follow-up due to the fact that patients who withdrew from 
the studies prematurely were not followed for fatal events 
to the end of the pre-defined treatment period in any of the 
trials analyzed by Singh et al.64 In contrast to the conclu-
sions of the latter authors, the UPLIFT trial, in which fatal 
events were captured in nearly all patients throughout the 
entire pre-defined 4-year treatment period even in those 
who withdrew prematurely, found a significant 13% reduc-
tion in all-cause mortality (risk ratio [RR] 0.87 [95% CI, 
0.76–0.99]) and a significantly reduced risk ratio (RR 0.78 
[95% CI, 0.65-0.94]) for the same composite fatal/nonfatal 
cardiovascular index for which Singh et al64 found an elevated 
risk, as well as a significantly reduced (rather than elevated) 
risk ratio (RR; 0.73 [95% CI, 0.65-0.94]) for cardiovascular 
deaths specifically.20 Moreover, analysis of serious adverse 
events in UPLIFT showed significantly reduced risk ratios 
for MI (RR 0.84 [95% CI, 0.77-0.99]) and congestive heart 
failure (0.59 [95% CI, 0.37-0.96]) and no increased risk of 
stroke (0.95 [95% CI, 0.70-1.29]), including fatal stroke 
(0.82 [95% CI, 0.40-1.66]).20 Confirmatory findings from 
a pooled analysis of cardiovascular safety using data from 
30 tiotropium double-blind, parallel-group, placebo-con-
trolled trials of 4 weeks duration (including UPLIFT) 
have recently been reported.65 These findings should dispel 
earlier concerns about the cardiovascular safety of tiotropium, 
including the risk of stoke.
Other adverse events
According to a pooled safety analysis of data from 19 clini-
cal trials in 4435 tiotropium and 3384 placebo patients, dry 
mouth (RR 3.60 [2.56-5.05]) was one of the most commonly 
reported adverse events.66 The RR for urinary retention 
was elevated (10.93 [95% CI, 1.26-94.8]), but this event 
was quite rare (incidence rate 0.78 per 100-patient years in 
tiotropium-treated subjects). Other side effects, including 
constipation and visual blurring, were consistent with the 
known pharmacology of anticholinergic agents and occurred 
infrequently. Thus, it can be concluded that tiotropium is 
well-tolerated with a highly favorable benefit/risk ratio.
Conclusions
Exacerbations of COPD are acute events superimposed on 
the course of this chronic disease that are associated with 
increased morbidity and mortality and account for most of 
the economic health care burden of the disease. Consequently, 
the prevention and treatment of acute exacerbations are a 
major goal in COPD management. Several double-blind, 
randomized placebo-controlled trials of 3 months to 4 years   
duration in patients with moderate to very severe COPD have International Journal of COPD 2010:5 52
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demonstrated the effectiveness of tiotropium in reducing 
both the proportion of patients experiencing at least one 
exacerbation and the exacerbation incidence rate and in 
prolonging the time to the first exacerbation. In some studies, 
including the 4-year UPLIFT trial, tiotropium also had a ben-
eficial effect in reducing the risk of hospitalization for an exac-
erbation. The mechanism whereby tiotropium produces these 
benefits probably relates to its effect in producing sustained 
bronchodilation and reduction in hyperinflation, thus raising 
the threshold for experiencing symptoms during insults that 
might otherwise lead to an exacerbation. In the management 
of an acute exacerbation, an increase in short-acting broncho-
dilators is recommended; the potential role of regular use of 
long-acting bronchodilators, such as tiotropium, in addition to 
short-acting agents as needed, requires further study.
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